We spoke with the founding director of the Center for Pulmonary Infection Research and Treatment, Charles Dela Cruz, MD, PhD, of Yale University to get a better understanding of the risks that COVID-19 may pose to patients with chronic lung disease.
The COPD Foundation released practical recommendations for patients living with COPD who may have concerns about COVID-19.
The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.
A typical usual interstitial pneumonia pattern was the predominant radiologic pattern seen in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
Patients with established chronic lung allograft dysfunction may have a higher risk for respiratory syncytial virus infections, but lung function decline does not appear to be significantly affected.
Individuals representing some of the nation’s preeminent medical organizations have called for “reasonable, evidence-based solutions” to reduce injury and death related to firearms.
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Performing therapeutic bronchoscopy at the time of intensive care unit admission may decrease ventilator-associated pneumonia incidence in patients with level I trauma.
The most common findings in patients with Chagas cardiomyopathy include cardiac rhythm abnormalities, myocardial abnormalities, aneurysms, and thromboembolism.
Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.
